Skip to content
thestock.space

As of 6 Nov 2026, Abbott India trades at 34.7× trailing earnings, above the industry P/E of 28.7×, and the shares are 14% below their 52-week high. Sales and net profit grew 9.0% and 18% a year over 3 years; its ROCE of 42% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 2.0%. It is a mid-cap company with a market cap of ₹55,981 Cr, ranked 13th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 9.4% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹26,615.00
Day high
₹27,065.00
Day low
₹26,280.00
Prev. close
₹26,605.00
Volume
17K

Health check

2 good · 2 fair · 2 to check
  • ReturnsBehind

    −9.4% over a year, better than 0 of 7 peers.

  • Price tagPricier

    P/E 34.7 vs industry 28.7.

  • GrowthSteady

    Sales +9.0%, profit +17.8% a year over 3 years.

  • ProfitabilityStrong

    ROCE 41.9% vs peer median 17.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Mid cap

₹55,981 Cr, #13 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹7,004 Cr · profit ₹1,615 Cr
Market cap
₹55,981 Cr
Mid cap
P/E
34.7
Industry 28.7
Price to book
11.73
Peers 4.99
Dividend yield
1.97%
ROE
34.5%
Peers 14.7%
ROCE
41.9%
Peers 17.9%
Debt to equity
0.04
Debt ₹172 Cr
EPS (TTM)
₹759.84
Face value ₹10
OPM (TTM)
28.1%
Net margin 23.1%
Sales growth
+4.3%
Latest quarter vs a year ago
Profit growth
+17.1%
Latest quarter vs a year ago
Price to sales
7.99
EV/EBITDA 28.0

Strengths and risks

Strengths

  • Return on equity of 34.5%.
  • Return on capital employed of 41.9%.
  • Practically debt-free.
  • Net margin of 23.1%.
  • Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Abbott India

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, hypothyroidism, central nervous system, vaccines, and multispecialty, including insomnia, vertigo, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, respiratory,…

Headquarters
Mumbai
Employees
3,679
Sector
Healthcare
ISIN
INE358A01014
Website
abbott.co.in

Price range

52 weeks

₹24,650.00₹30,655.00

Today

₹26,280.00₹27,065.00
Avg volume (3M)
8.5K
1-year return
minus 9.4%
From 52-week high
minus 14.1%

Analyst consensus

8 analysts
No consensusMean target ₹32,467.38 plus 23.2%

Target range, with today’s price

Low ₹29,900.00High ₹38,100.00

Today’s price ₹26,345.00 is below the lowest analyst target.

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
ABBOTINDIAAbbott India26,345.00minus 0.98%55,98134.711.7341.9%34.5%28.1%9.0%17.8%1.97%minus 9.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
1,7381,7571,7241,7101,814
1,2931,2551,2611,2291,291
446502463481523
25.6%28.6%26.9%28.1%28.8%
72.87069.875.675.4
5.87.65.56.15.9
19.518.618.819.119.8
493546509531572
25.8%23.9%26.1%25.7%25.1%
366415376395429
172.17195.42176.92185.85201.66

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+9.0%
Profit CAGR 3Y
+17.8%
EPS CAGR 3Y
+17.8%
ROE
34.5%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
5,3475,8476,4076,927
–+9.4%+9.6%+8.1%
4,1294,3704,6915,026
1,2171,4771,7161,901
22.8%25.3%26.8%27.4%
142223258272
1612.511.425
7071.271.876
11.6−3.87.6
1,2741,6181,8872,079
25.5%25.7%25.0%25.4%
9491,2011,4141,552
–+26.5%+17.8%+9.7%
446.78565.28665.62730.36

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
21.321.321.321.3
3,1673,6784,2124,753
11383.2197172
1,2541,4111,4871,556
4,5565,1935,9176,502
234229351333
4.510.3215.8
1,2041,6527412,330
1,9222,1183,1132,232
1,1901,1841,6911,600
4,5565,1935,9176,502

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
8931,2131,0121,319
−148−416182−371
−639−745−925−1,066
10752.1269−118
−34.1−48.3−52.6−40.9
8591,1649591,278
−584−691−871−1,009

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 6.9% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you